Home - Products - Angiogenesis - EGFR - Alflutinib methanesulfonate

Alflutinib methanesulfonate

CAS No. 2130958-55-1

Alflutinib methanesulfonate ( AST2818;AST-2818;ASK120067 )

Catalog No. M13393 CAS No. 2130958-55-1

Alflutinib methanesulfonate (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 149 In Stock
10MG 222 In Stock
25MG 374 In Stock
50MG 555 In Stock
100MG 790 In Stock
500MG 1611 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Alflutinib methanesulfonate
  • Note
    Research use only, not for human use.
  • Brief Description
    Alflutinib methanesulfonate (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor.
  • Description
    Alflutinib methanesulfonate (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor, inhibits EGFR active mutations as well as T790M acquired resistant mutation.Lung Cancer Phase 1 Clinical
  • Synonyms
    AST2818;AST-2818;ASK120067
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    EGFR
  • Research Area
    Cancer
  • Indication
    Lung Cancer

Chemical Information

  • CAS Number
    2130958-55-1
  • Formula Weight
    664.71
  • Molecular Formula
    C29H35F3N8O5S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : 5 mg/mL 7.52 mM
  • SMILES
    CN(C)CCN(C)c1nc(OCC(F)(F)F)c(Nc2nccc(n2)c3cn(C)c4ccccc34)cc1NC(=O)C=C.CS(=O)(=O)O
  • Chemical Name
    N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)acrylamide methanesulfonate

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. PCT Int. Appl. (2017), WO 2017152707 A1 20170914.
2. PCT Int. Appl. (2017), WO 2017152706 A1 20170914.
molnova catalog
related products
  • Peiminine

    Peiminine is an effective inhibitor for lung inflammation and pulmonary fibrosis in a rat model of bleomycin-induced lung injury.

  • EGF816 mesylate

    EGF816 (Nazartinib) is a potent, irreversible, mutant-selective EGFR inhibitor with Ki and Kinact of 31 nM and 0.222 min-1, respectively.

  • CCF642

    CCF642 is a novel PDI-inhibiting compound with antimyeloma activity.